Target：FPR1
Fields：Rap1 signaling pathway;Neuroactive ligand-receptor interaction;Neutrophil extracellular trap formation;Staphylococcus aureus infection
Gene Name：FPR1
Protein Name：fMet-Leu-Phe receptor
Human Gene Id：2357
Human Swiss Prot No：P21462
Mouse Swiss Prot No：P33766
Immunogen：The antiserum was produced against synthesized peptide derived from human FPR1. AA range:155-204
Specificity：FPR1 Polyclonal Antibody detects endogenous levels of FPR1 protein.
Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source：Polyclonal, Rabbit,IgG
Dilution：WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:5000. Not yet tested in other applications.
Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration：1 mg/ml
Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)
Other Name：FPR1;fMet-Leu-Phe receptor;fMLP receptor;N-formyl peptide receptor;FPR;N-formylpeptide chemoattractant receptor
Observed Band(KD)：40kD
Background：formyl peptide receptor 1(FPR1) Homo sapiens This gene encodes a G protein-coupled receptor of mammalian phagocytic cells that is a member of the G-protein coupled receptor 1 family. The protein mediates the response of phagocytic cells to invasion of the host by microorganisms and is important in host defense and inflammation.[provided by RefSeq, Jul 2010],
Function：function:High affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system.,PTM:Phosphorylated; which is necessary for desensitization.,similarity:Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Neutrophils.,
Subcellular Location：Cell membrane ; Multi-pass membrane protein . Internalizes in presence of its ligands, fMLP, TAFA4 and CTSG. .
Expression：Neutrophils.
